CHMP recommended granting a Conditional Marketing Authorisation for Elrexfio (elranatamab) for the treatment of adult patients with relapsed or refractory multiple myeloma.

On 13 October 2023, the CHMP released its Positive recommendations on new medicine

- Elrexfio (elranatamab) - Pfizer

The committee recommended granting a Conditional Marketing Authorisation for Elrexfio (elranatamab), for the treatment of adult patients with relapsed or refractory multiple myeloma.

Indication:

Elrexfio is indicated as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody and have demonstrated disease progression on the last therapy.